TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06139887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BESST
Description: The BESST intervention is a suicide prevention program designed to meet the unique needs of Veterans receiving care from community mental health treatment settings. BESST can be delivered by a trained mental health staff member, such as a mental health nurse, social worker, psychologist, or psychiatrist. The intervention consists of two synergistic components that work to support the patient after a mental health-related discharge in community settings: 1) Brief educational session, where the patient receives a one-hour, one-on-one, personalized educational session on suicide prevention; 2) Seven regular contacts after discharge, where the study interventionist who delivered the brief educational visit will contact the patient to monitor the patient's symptoms, assess treatment adherence, review their safety plan, and assist the patient with engaging in care, if needed.
Study: NCT05965518

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training
Description: Following a 5-minute warm-up at 50% VO2peak, high and moderate-intensity exercise bouts alternate, progressing to five bouts of 4-minute high-intensity exercise (90% VO2peak), alternating with four 3-minute bouts of moderate-intensity exercise (50% VO2peak) by week 8, followed by a 5 minute cool-down. The total exercise time is 42 minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Moderate Exercise
Description: Following a 4 minute warm-up at 50% VO2peak, the participant walks for up to 42 continuous minutes at 60% VO2peak, followed by a 4 minute cool-down. The total exercise time is 50 minutes.
Study: NCT06139887

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Mental Health Care
Description: Patients randomized to the control arm will receive standard mental health care alone. Standard mental health care simply refers to the regular care provided to patients around the time of discharge from community care settings.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Mental Health Care
Description: Patients randomized to the control arm will receive standard mental health care alone. Standard mental health care simply refers to the regular care provided to patients around the time of discharge from community care settings.
Study: NCT05574569

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 1: Play Therapy
Description: Play therapy will be given to children having emotional and behavioral problems.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 2: Mindful Parenting
Description: Culturally adapted mindful parenting worksheets will be given to the parents of children having emotional and behavioral problems.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group 3: (Combined Interventions of both Group 1 & 2)
Description: Play therapy will be given to children and in addition, culturally adapted mindful parenting worksheets will be given to the parents of children having emotional and behavioral problems.
Study: NCT05972096

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combination DBT, self-compassion and contextual-based skills
Description: Psychotherapy combination. Skills of DBT plus self-compassion and contextual skills

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Combination DBT, self-compassion and contextual-based skills
Description: Psychotherapy combination. Skills of DBT plus self-compassion and contextual skills
Study: NCT06063226

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: Orally administred probiotics with L. plantarum and L. rhamnosus

Intervention type: OTHER
Group type: OTHER
Intervention: Negative control
Description: Only routinary oral hygiene procedures

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Positive control
Description: Orally administred placebo without probiotics
Study: NCT05461625

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: ACL reconstruction
Description: Anterior cruciate ligament reconstruction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL reconstruction
Description: Anterior cruciate ligament reconstruction

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL reconstruction
Description: Anterior cruciate ligament reconstruction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ALL anatomic
Description: anatomic anterolateral ligament reconstruction

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ALL tenodesis
Description: anterolateral ligament teondesis
Study: NCT05774964

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin via intravenous drip on d1 at a dose of 130 mg/m2 × patient 's body surface area

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin via intravenous drip on d1 at a dose of 130 mg/m2 × patient 's body surface area

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin via intravenous drip on d1 at a dose of 130 mg/m2 × patient 's body surface area

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: Orally on d2-d15 at 20 mg three times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: Orally on d2-d15 at 20 mg three times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: Orally on d2-d15 at 20 mg three times daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab combined with chemotherapy was administered simultaneously, once every three weeks,and intravenous drip was performed before oxaliplatin at a dose of 250 mg/m2 × body surface area.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab combined with chemotherapy was administered simultaneously, once every three weeks,and intravenous drip was performed before oxaliplatin at a dose of 250 mg/m2 × body surface area.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole 0.4g/time, qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: Vitamin A 5,000 units/time, qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: Folic acid 5 mg/time, qd
Study: NCT04982419

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic preconditioning
Description: 3 cycles of blood pressure cuff inflations to occlusive pressure of 200 mmHg for 5 minutes and deflation for 5 minutes

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham remote ischemic conditioning
Description: 3 cycles of blood pressure cuff inflations to non-occlusive pressure of 60 mmHg for 5 minutes and deflation for 5 minutes (Control)
Study: NCT04145050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate dosing
Description: The purpose of this study is to examine effects of different carbohydrate doses during marathon simulation in elite wheelchair racers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate dosing
Description: The purpose of this study is to examine effects of different carbohydrate doses during marathon simulation in elite wheelchair racers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carbohydrate dosing
Description: The purpose of this study is to examine effects of different carbohydrate doses during marathon simulation in elite wheelchair racers.
Study: NCT05847465

Intervention type: OTHER
Intervention: Bike stress test
Description: This is an incremental exercise under maximal pedaling on an Excalibur® type bike with electromagnetic brake over 36 minutes during which gas exchanges are continuously measured through a face mask (Cosmed®).

Intervention type: OTHER
Intervention: Bike stress test
Description: This is an incremental exercise under maximal pedaling on an Excalibur® type bike with electromagnetic brake over 36 minutes during which gas exchanges are continuously measured through a face mask (Cosmed®).

Intervention type: OTHER
Intervention: Heat Tolerance Test
Description: The test consists of a walk on a treadmill in shorts, bare chest or bra for women, at 5 km/h and 2% slope in an environment at 40°C, 40% relative humidity, without convection.~During the test, rectal temperature, heart rate and skin temperature will be monitored continuously.~The blood pressure will be measured manually every 30 minutes during the test.

Intervention type: OTHER
Intervention: Heat Tolerance Test
Description: The test consists of a walk on a treadmill in shorts, bare chest or bra for women, at 5 km/h and 2% slope in an environment at 40°C, 40% relative humidity, without convection.~During the test, rectal temperature, heart rate and skin temperature will be monitored continuously.~The blood pressure will be measured manually every 30 minutes during the test.

Intervention type: OTHER
Intervention: Heat nociception test
Description: This test consists in applying a thermal flux generated by an infrared light source on a beam of 1 cm diameter on 2 areas of the dominant lower limb (glabrous face of the forearm and thenar eminence).~Participants will be instructed to remove their limb as soon as the sensation of heat begins to become uncomfortable.~The time between the beginning of the stimulus and the moment of withdrawal will be recorded.
Study: NCT05914155

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab (genetical recombination)
Description: Administer 1,000 mg of rituximab (genetical recombination) IV infusion every two weeks for two doses in double-blind phase.
Study: NCT05847465

Intervention type: OTHER
Intervention: Heat nociception test
Description: This test consists in applying a thermal flux generated by an infrared light source on a beam of 1 cm diameter on 2 areas of the dominant lower limb (glabrous face of the forearm and thenar eminence).~Participants will be instructed to remove their limb as soon as the sensation of heat begins to become uncomfortable.~The time between the beginning of the stimulus and the moment of withdrawal will be recorded.
Study: NCT06210035

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Belly-focus meditation
Description: Participants will engage in concentration meditation for 40 minutes every day for a week. They will focus on the sensations around the belly.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Belly-focus meditation with slow breathing
Description: Participants will engage in concentration meditation and slow breathing for 40 minutes every day for a week. They will focus on the sensations around the belly while breathing slowly.
Study: NCT05727839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JCXH-211 Injection
Description: JCXH-211 administered once every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JCXH-211 Injection
Description: JCXH-211 administered once every 28 days
Study: NCT06307132

Intervention type: OTHER
Intervention: Aximus capsules（test）
Description: Aximus capsules test preparation

Intervention type: DRUG
Intervention: Aximus capsules（reference）
Description: Aximus capsules reference preparation
Study: NCT05914155

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administer placebo IV infusion every two weeks for two doses in double-blind phase.
Study: NCT06577506

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deaf Diabetes Can Together
Description: 10-week diabetes self-management telehealth intervention for deaf adults with diabetes.
Study: NCT06576869

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upper extremity orthopedic surgeries.
Description: Upper extremity orthopedic surgeries that require the use of a tourniquet.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Upper extremity orthopedic surgeries.
Description: Upper extremity orthopedic surgeries that require the use of a tourniquet.
Study: NCT06576609

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INJEX [ Needle less anesthesia]
Description: already described

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: INJEX [ Needle less anesthesia]
Description: already described
Study: NCT05760989

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Edwards EWJ-202 Transcatheter Tricuspid Valve Replacement System
Description: Replacement of the native tricuspid valve through a transcatheter approach
Study: NCT06575673

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based dialectical behaviour therapy-informed skills training
Description: Adaptive applications of DBT-ST for smokers with psychological distress

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Monthly health education
Description: General health information and sharing sessions
Study: NCT06576531

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic exercise
Description: A stepped training intervention designed ad hoc based on a combination of aerobic and strength exercises.
Study: NCT06368271

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipidomics
Description: Health beneficial effects of medium-chain fatty acids
Study: NCT05914155

Intervention type: DRUG
Group type: OTHER
Intervention: Rituximab (genetical recombination)
Description: Patients who remain to be ICR II (Incomplete Remission Type II) or NR (No Response) until Week 26 in the double-blind phase, if the patients wish to move to the open-label phase and the investigator or a subinvestigator considers the move necessary, the patient will move to the open-label phase and receive 1,000 mg of rituximab (genetical recombination) IV infusion every two weeks for two doses after the readministration criteria are confirmed to be met.
Study: NCT06029920

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Overground Walking
Description: Walk on a flat surface for a distance of 15 meters, with a duration of 20 minutes, increasing by 5 minutes each week until the target heart rate is achieved during the exercise, for 8 weeks.
Study: NCT05829629

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FluBHPVE6E7
Description: Intracervical administration for first dose followed by intramuscular administration for subsequent doses at recommended dose level and determined schedule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intracervical administration for first dose followed by intramuscular administration for subsequent doses at determined schedule
Study: NCT05110937

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling
Study: NCT05421429

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KN057 doseⅠ
Description: KN057 subcutaneous (SC) injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KN057 dose Ⅱ
Description: KN057 SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KN057 dose Ⅱ
Description: KN057 SC injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KN057 dose Ⅲ
Description: KN057 SC injection
Study: NCT04756687

Intervention type: DRUG
Intervention: Dimethyl fumarate
Description: Administered as specified in the treatment arm.
Study: NCT06517043

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Balance Training
Description: Complex balance task involving static and dynamic weight shifting and coordinated stepping
Study: NCT05659745

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VM-02
Description: VM-02 is a personal care product for vaginal health.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VM-02
Description: VM-02 is a personal care product for vaginal health.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VM-02
Description: VM-02 is a personal care product for vaginal health.
Study: NCT06517043

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Balance Training
Description: Complex balance task involving static and dynamic weight shifting and coordinated stepping

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Active tsDCS
Description: Active tsDCS over lumbar regions

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Spinal Sham tsDCS
Description: Sham tsDCS over lumbar regions
Study: NCT05452057

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: A Registered Kinesiologist will provide your exercise prescription during your first visit for the study. Your exercise sessions will consist of moderate-intensity cardiovascular (or aerobic) exercise, like brisk walking, for 30 minutes. You will also perform resistance exercises (weight lifting) for 30 minutes that will help strengthen your muscles with a focus on muscles that may be affected by your surgery. To complete your exercises, you will receive resistance bands, exercise ball, and exercise manual.~You will also meet with a Registered Dietician within a week of consent to receive information on healthy eating and you will receive protein to improve your nutritional health.~A consult with an expert in psychology to discuss ways to reduce your stress within a week of consent. Some strategies to help reduce your stress may include breathing exercises, being mindful, or other relaxation methods.
Study: NCT06505187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 200mg every 12 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tylenol
Description: 650mg q6h

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Tylenol
Description: 650mg q6h
Study: NCT05110937

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling
Study: NCT06505187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: 5mg every 6 hours as needed

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Oxycodone
Description: 5mg every 6 hours as needed

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: placebo
Description: every 12 hours
Study: NCT05659745

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Commercial Oral Probiotic Competitor
Description: Commercial Oral Vaginal Probiotic Competitor is a personal care product for vaginal health.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: VM-02 Placebo
Description: VM-02 Placebo is a personal care product placebo for vaginal health.
Study: NCT06127485

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuropilates+occupational therapy and physiotherapy conventional
Description: Participants assigned to the experimental group received 60 minutes of conventional rehabilitation combined with the Pilates Method, divided into 20 minutes of physical therapy, 20 minutes of occupational therapy and 20 minutes of Pilates Method. Pilates routines will be performed on a mat through the practice of Pilates activation exercises. Each participant will be given the necessary adaptations of each exercise according to their difficulties/disabilities.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Occupational Therapy and Physiotherapy conventional
Description: Conventional physical therapy in both groups will include stretching techniques and muscle activation of the lower limb and gait reeducation. Conventional occupational therapy will include stretching techniques and muscle activation in the upper limb as well as training in activities of daily living and functional activities of the upper limb.
Study: NCT04618575

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid combined with total glucosides of paeony
Description: Ursodeoxycholic acid combined with total glucosides of paeony

Intervention type: DRUG
Group type: OTHER
Intervention: Ursodeoxycholic acid only
Description: Ursodeoxycholic acid only
Study: NCT05727553

Intervention type: RADIATION
Intervention: Online adaptive radiotherapy
Description: Postoperative radiotherapy will be indicated conform the standard medical care and guidelines. The radiation is delivered with online adaptive radiotherapy performed on the Ethos. This technique will be evaluated.
Study: NCT05654961

Intervention type: OTHER
Intervention: Use of telemedicine
Description: Use of telemedicine (any type: telephone only, non-invasive, implantable-cardioverter-defibrillator-based, invasive) in heart failure management
Study: NCT06645808

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 89Zr-DFO-N-Suc-F8scFv
Description: 89-Zirconium labeled short-chain variable fragment F8 targeting oncofetal CS.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 89Zr-DFO-N-Suc-C9scFv
Description: 89-Zirconium labeled short-chain variable fragment C9 targeting oncofetal CS.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET/CT scan
Description: IMP administration will be followed by PET/CT scans on day 1, 2 and 4.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PET/CT scan
Description: IMP administration will be followed by PET/CT scans on day 1, 2 and 4.
Study: NCT06670989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fixation training
Description: Training (adapting) microsaccades during fixation
Study: NCT06670339

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Cooling
Description: Participants will not be pre-cooled prior to completing a 60-minute moderate-intensity exercise bout in the heat.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-Cooling
Description: Participants will be immersed in cold (\~17°C) water to elicit a decrease in rectal temperature by 0.5°C from baseline values prior to completing a 60-min moderate-intensity exercise bout in the heat.
Study: NCT06613217

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zelenirstat
Description: Zelenirstat will be administered orally, once daily, on 28-day cycles, at the same time each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zelenirstat
Description: Zelenirstat will be administered orally, once daily, on 28-day cycles, at the same time each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zelenirstat
Description: Zelenirstat will be administered orally, once daily, on 28-day cycles, at the same time each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zelenirstat
Description: Zelenirstat will be administered orally, once daily, on 28-day cycles, at the same time each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zelenirstat
Description: Zelenirstat will be administered orally, once daily, on 28-day cycles, at the same time each day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zelenirstat
Description: Zelenirstat will be administered orally, once daily, on 28-day cycles, at the same time each day.
Study: NCT06627920

Intervention type: DEVICE
Intervention: Use of the KC08 smartwatch, Beurer PO30 and Omron M7 BP monitor.
Description: Use of the KC08 smartwatch, Beurer PO30 and Omron M7 BP monitor to estimate blood pressure, heart rate and oxygen saturation.